Company news
Journey Medical Corporation news in 2023
Journey Medical Corporation's news releases, calls and decks from 2023, newest first.
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
December 5, 2023
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 6, 2023
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023
October 30, 2023
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 vs. Solodyn
October 23, 2023
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)
October 19, 2023
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations
September 5, 2023
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 7, 2023
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023
August 1, 2023
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
July 18, 2023
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
July 12, 2023
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
July 10, 2023
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of...
July 2, 2023
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects
June 12, 2023
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 21, 2023
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
May 18, 2023
Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call
May 10, 2023
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023
May 3, 2023
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
March 28, 2023
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023
March 21, 2023
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 on Microbial Flora in a Separate Phase 1 Clinical Trial
March 17, 2023
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
March 15, 2023
Journey Medical Corporation to Participate in the 35th Annual ROTH Conference
March 6, 2023
Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer
January 19, 2023
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea
January 11, 2023
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea
January 9, 2023